Palatin Technologies, Inc. — Form 10-Q Summary
Reporting period: Quarter ended March 31, 2018, the third quarter of fiscal 2018 (not 2017 Q3 as stated in the request metadata). Unaudited consolidated results. Palatin is a clinical-stage biopharmaceutical company; it had no product sales, and reported revenue from license and collaboration agreements.
Financial performance and liquidity
| Metric | Three months ended March 31, 2018 | Nine months ended March 31, 2018 | Comparable 2017 period |
|---|---|---|---|
| License and contract revenue | $9.0 million | $46.5 million | $10.8 million for both periods |
| Operating expenses | $9.5 million | $32.9 million | $13.8 million and $35.7 million |
| Operating income (loss) | $(0.5) million | $13.7 million | $(3.0) million and $(24.9) million |
| Net income (loss) | $(0.7) million | $12.9 million | $(3.6) million and $(26.6) million |
| Net cash from (used in) operations | Not stated for the quarter | $(8.8) million | $25.8 million for nine months |
- Nine-month 2018 revenue included $41.5 million recognized under the AMAG agreement and a $5.0 million Fosun upfront license fee. AMAG revenue was $9.0 million in the quarter. The filing reports no gross profit or gross margin.
- Research and development expense was $27.3 million for nine months, down from $28.4 million; general and administrative expense was $5.6 million, down from $7.3 million. The G&A reduction primarily reflected professional fees related to the AMAG transaction in the prior-year period.
- At March 31, cash and cash equivalents were $25.7 million, versus $40.2 million at June 30, 2017. Total assets were $27.2 million; total liabilities were $16.9 million. Current liabilities were $14.2 million, including $0.6 million of deferred revenue; management cited $13.6 million net of that deferred revenue.
- Notes payable, net of discounts and issuance costs, totaled $8.25 million ($6.92 million current and $1.33 million long-term). The debt bears interest at one-month LIBOR plus 8.5%; scheduled principal repayments extend through January 2019 and August 2019. Palatin reported compliance with loan covenants.
- Nine-month cash use also included $5.9 million net financing outflow, principally $6.0 million of debt payments. Cash declined by $14.5 million overall. No cash-flow figure for the quarter alone is provided.
Changes, outlook, and material developments
- Revenue and earnings improved sharply for the nine-month period versus 2017, principally because of AMAG license-related revenue and the Fosun upfront payment. The quarter itself remained loss-making, with lower revenue than the prior-year quarter.
- AMAG submitted an NDA to the FDA for bremelanotide for HSDD in premenopausal women in March 2018. Palatin reported that its two Phase 3 studies met their prespecified co-primary endpoints; commonly reported adverse events included nausea, flushing, and headache, generally mild to moderate and transient.
- Palatin licensed bremelanotide commercialization rights in China and specified Asian territories to Fosun and in Korea to Kwangdong. Potential future milestone and royalty receipts are contingent; the filing does not present them as assured revenue. Palatin retains rights outside North America, Korea, and China and was seeking additional partners for other territories.
- Other programs include PL-8177, which began a Phase 1 safety study in February 2018; PL-3994, with Phase 2A trials scheduled to start later in calendar 2018; and PL-8331, for which IND-enabling work was expected later in 2018. These are forward-looking plans, not reported outcomes.
- Management stated existing capital resources, together with possible at-the-market sales, were expected to fund planned operations through at least June 30, 2019. It also said additional funding would be needed for trials and regulatory work on other candidates. Management expects further losses and cautioned sustained profitability is uncertain.
- After quarter-end, Palatin entered an at-the-market equity distribution agreement on April 20, 2018. By May 11, it had sold 203,900 shares for net proceeds of $243,696. It also received $2.4 million from warrant exercises between April 1 and May 11; 2,995,807 shares were issued. Outstanding common shares were 198,677,039 as of May 11.
- Nine-month net income included a $500,000 tax benefit related to release of an allowance against an alternative minimum tax credit. The filing also notes withholding-tax expenses associated with the Fosun and Kwangdong agreements. These items, along with license revenue recognition, make reported earnings a limited indicator of recurring operating performance.
Key risks and items to verify
- FDA review outcome and timing for the bremelanotide NDA, including any requests for additional data, manufacturing validation, or device-related requirements.
- Whether Palatin’s cash runway remains consistent with management’s estimate, and whether additional equity, debt, licensing, or collaboration financing will be required. The filing warns financing may not be available on acceptable terms or at all.
- AMAG’s ability and willingness to obtain approval and commercialize bremelanotide; future milestones and royalties depend on regulatory and commercial success.
- Potential dilution: common shares outstanding rose from 160.5 million at June 30, 2017 to 195.5 million at March 31, 2018; the filing also describes substantial outstanding options, restricted stock units, and warrants.
- Whether planned clinical development for PL-8177, PL-3994, and other candidates proceeds on schedule and can be funded. Clinical, regulatory, manufacturing, reimbursement, competition, and partner-performance risks remain material.
- License-revenue timing and concentration: 2018 results depended heavily on AMAG-related recognition and upfront licensing payments, while Palatin reported no product-sale revenue. Verify how subsequent accounting and development progress affect deferred revenue and recurring cash needs.